Corvus Pharmaceuticals, Inc. (17) | Uncategorized (8)

Recent Contracts

Open Market Sale Agreement, dated November 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on March 10, 2022)
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2021)
Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on October 29, 2020)
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2020)
Amendment No. 1 to the Phase I/IB Combination Study Agreement, dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)
Amendment No. 2 to the Phase I/IB Combination Study Agreement, dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)
Amendment No. 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc (Filed With SEC on March 9, 2020)
Offer Letter, dated as of January 7, 2019 by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher (Filed With SEC on March 7, 2019)